Prometheus Biosciences Inc (RXDX)
Prometheus Biosciences is a biotechnology company developing a precision medicine approach to the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting with inflammatory bowel disease. Co. utilizes its proprietary precision medicine platform, Prometheus360, which includes a gastrointestinal bioinformatics database and sample biobank, to identify therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, Co. is developing companion diagnostic tests designed to identify patients more likely to respond to our therapeutic candidates.
|
March 29, 2024 12:46 AM Eastern
Buy (2.67 out of 4)
100th percentile
|
|